SP323EFFECTS OF RVX-208, A FIRST IN CLASS EPIGENETIC BET INHIBITOR, ON KEY RENAL PARAMETERS IN SUBJECTS WITH A HISTORY OF CVD, AND CHRONIC KIDNEY DISEASE (CKD); A POST-HOC ANALYSIS OF PATIENTS FROM THE ASSERT, SUSTAIN AND ASSURE CLINICAL TRIALS

EFFECTS OF APABETALONE (RVX-208) ON SERUM ALBUMIN IN SUBJECTS WITH CVD, DIABETES AND CHRONIC KIDNEY DISEASE; A POST-HOC ANALYSIS OF THE ASSURE AND SUSTAIN CLINICAL TRIALS

SP071APABETALONE (RVX-208), A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, DECREASES ABUNDANCE AND ACTIVITY OF COMPLEMENT PROTEINS IN VITRO, IN MICE AND IN CLINICAL STUDIES

DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR APABETALONE ON KIDNEY FUNCTION AND MACE IN POST-ACS PATIENTS WITH ESTIMATED GLOMERULAR FILTRATION RATE BELOW 60 AND DIABETES

APABETALONE (RVX-208) IMPACTS KEY BIOMARKERS AND PATHWAYS ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN PATIENTS WITH SEVERE RENAL IMPAIRMENT

INHIBITION OF BET PROTEINS WITH APABETALONE REDUCES MEDIATORS OF VASCULAR CALCIFICATION IN VITRO AND IN CKD PATIENTS

Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial

Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study

THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL

APABETALONE, A BROMODOMAIN AND EXTRATERMINAL PROTEIN INHIBITOR, DECREASES KEY FACTORS IN VASCULAR CALCIFICATION IN VITRO AND IN CLINICAL TRIALS